Evidence map›Paper›PMID 29558679›Full record

ArticleNeoplasia (New York, N.Y.)2018

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Karin Kfir-Elirachman, Rona Ortenberg, Bella Vizel, Michal J Besser, Iris Barshack, Jacob Schachter, Yael Nemlich, Gal Markel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Karin Kfir-ElirachmanElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rona OrtenbergElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel.
Bella VizelElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Michal J BesserElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Iris BarshackInstitute of Pathology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, 5262620, Israel.
Jacob SchachterElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, 5262620, Israel.
Yael NemlichElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel.
Gal MarkelElla Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: Gal.Markel@Sheba.health.gov.il.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF becomes constitutively activated in 50% to 70% of melanoma cases. CEACAM1 has a dual role in melanoma, including facilitation of cell proliferation and suppression of infiltrating lymphocytes, which are consistent with its value as a marker for poor prognosis in melanoma patients. Here we show that BRAF

Indexed as

Antigens, CDCell Adhesion MoleculesCell Line, TumorCell ProliferationDown-RegulationDrug Resistance, NeoplasmHumansIndolesMAP Kinase Signaling SystemMelanomaPromoter Regions, GeneticProtein Kinase InhibitorsProto-Oncogene Protein c-ets-1Proto-Oncogene Proteins B-rafRNA, MessengerSulfonamidesAntigens, CDBRAF protein, humanCD66 antigensCell Adhesion MoleculesETS1 protein, humanIndolesProtein Kinase InhibitorsProto-Oncogene Protein c-ets-1Proto-Oncogene Proteins B-rafRNA, MessengerSulfonamidesTranscription FactorsVemurafenib

Identifiers

PMID29558679
PMCPMC5909674
OpenAlexW2789511986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.